Emphasis on Drug Class (Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, and Combination Drugs); Route of Administration (Inhalation, Enteral, and Parental); Distributional Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), and Pleural Effusion); Region/Country
The global respiratory drug Market is anticipated to grow with a CAGR of around 5% over the forecast period (2021-2027). The overall incidence of respiratory diseases has increased in recent decades due to rising pollution and industrialization. For instance, according to the Global Initiative for Chronic Obstructive Lung Disease, in 2019, globally around 384 million people suffer from COPD and ~3 million people die each year. Therefore, to reduce the number of cases or to provide the proper cure, the demand for respiratory drugs is increasing. Moreover, increasing the government’s focus on improving healthcare infrastructure to provide proper treatment to the patient is expected to boost the market for respiratory drugs. For instance, India’s National Health Policy (2017) aims to increase Government spending on health to 2.5% of GDP by 2025.
Abbott Laboratories, AbbVie Inc., Aerogen Pharma Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Celon Pharma S.A., Cipla Ltd., F. Hoffmann La Roche Ltd., and GlaxoSmithKline Plc, are some of the prominent players operating in the respiratory drug market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new and advanced drugs.
Insights Presented in the Report
“Amongst drug class, short-acting beta2-agonists (SABA) segment holds the major share”
Based on drug class, the market has been distributed into, short-acting beta2-agonists (SABA), long-acting beta 2-agonists (LABA), inhaled corticosteroids (ICS), anticholinergics, antihistamines, vasodilators, and combination drugs. Among these, SABA is known as a quick-acting and reliving drug from unforeseen asthma attacks, as it helps to rapidly open the airways. As, a large number of respiratory disease patients are suffering from asthma problems, therefore the demand for this drug class is high. Further, new technological advancements and product innovations are propelling its market demand. For instance, conventionally SABA is used as an injectable but with the advancement in technology, now it is also used in inhalers.
“Amongst disease types, chronic obstructive pulmonary disease (COPD) segment holds the major share”
Based on disease type, the market is categorized into asthma, chronic bronchitis, COPD, and pleural effusion. According to Global Initiative for Chronic Lung Disease, 384 million people suffer from COPD, and 3 million die from it each year, making it the third leading cause of death worldwide. As a result, the demand for drugs to treat the patients is considerably high for COPD. Further, environmental exposure to tobacco smoke, air pollution, occupational dust, fumes, and chemicals are important risk factors for COPD. This is likely to increase the cases of COPD in the foreseeable future, thereby boosting the market.
“North America represents one of the largest markets in respiratory drug market”
For a better understanding of the market dynamics of the respiratory drug market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, the United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, and Rest of APAC) and Rest of World has been conducted. North America constitutes a major market for the respiratory drug market industry in 2020 owing to the presence of well-established market players in the region and frequent drug launches.
Reasons to buy this report:
Customization Options:
The global respiratory drug market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Global Respiratory Drug Market Covid-19 Impact
6. Global Respiratory Drug Market Revenue, 2019-2027f
7. Market Insights By Drug Class
8. Market Insights By Disease Type
9. Market Insights By Route Of Administration
10. Market Insights By Distributional Channel
11. Market Insights By Region
12. Respiratory Drug Market Dynamics
13. Respiratory Drug Market Opportunities
14. Respiratory Drug Market Trends
15. Legal & Regulatory Framework
16. Demand And Supply-side Analysis
17. Value Chain Analysis
18. Competitive Scenario
19. Company Profiled
20. Disclaimer
Research Methodology for the Global Respiratory Drug Market Analysis (2021-2027)
Analyzing the historical market, estimation of the current market, and forecasting the future market of the global respiratory drug market were the three major steps undertaken to create and analyze the adoption of the respiratory drug in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global respiratory drug market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the respiratory drug through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the respiratory drug market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments included in the report as drug class, disease type, route of administration, and distributional channel. Further country-level analyses were conducted to evaluate the overall adoption of the respiratory drug across the globe.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis was conducted using dependent and independent variables such as technological advancement in the healthcare sector and growing demand for improved medical treatment. Historical trends and their year-on-year impact on the market size and share in the recent past were analyzed. The demand and supply-side scenario were also thoroughly studied.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the respiratory drug market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2027 for different segments and subsegments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, and Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the respiratory drug market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of drug class, disease type, route of administration, and distributional channel of the respiratory drug market.
The main objective of the Respiratory drug Market Study
The current & future market trends of the respiratory drug were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Deep dive regional level analysis of the industry
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
